GLP-1 drugs like Ozempic, Wegovy, and Zepbound are prescribed for weight loss, diabetes, and blood-sugar management. But as more people use them, patients are reporting a decrease in cravings for drugs and alcohol. Researchers are now investigating whether GLP-1s might be effective for treating alcohol and drug addiction.
How much do we know? What are the risks? And do these drugs tell us anything new about the biology of addiction?
Host Flora Lichtman talks with neuroscientist Joseph Schacht, who is conducting a clinical trial on GLP-1s and alcohol use; and Sarah Carstens, addictions clinical director of Outpatient Services at Penn Medicine’s Princeton House Behavioral Health.
Guests:
Dr. Joseph Schacht is the co-director of the Division of Addiction Science, Prevention, and Treatment at the University of Colorado Anschutz School of Medicine.
Sarah Carstens is the addictions clinical director of Outpatient Services at Penn Medicine’s Princeton House Behavioral Health.
Transcripts for each episode are available within 1-3 days at sciencefriday.com.
Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
